Clinical trials: Schizophreniform Disorder
First Episode Psychosis, Schizophrenia, Childhood
Early Psychosis Intervention - Spreading Evidence-based Treatment
Implementation of 'NAVIGATE' in Ontario aims to help youth and emerging adults suffering from a first episode of psychosis. Although Ontario already has early psychosis intervention programs, the team's recent work has identified…
- Conditions
- First Episode Psychosis, Schizophrenia, Childhood, Psychosis, Schizophrenia
- Trial name
- EPI-SET (NCT03919760)
- Testing
- NAVIGATE, Treatment as Usual
- Where
- 6 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder
Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl
The objective of this study is to evaluate the effect of calorie and fat content on the pharmacokinetics of Lurasidone HCl in subjects with schizophrenia, schizoaffective disorder, or schizophreniform disorder.
- Trial name
- NCT01074632
- Testing
- Lurasidone HCl
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizoaffective Disorder, Schizophreniform Disorder
Longitudinal PET Imaging of Antipsychotic Binding to the Dopamine-3 Receptor in Schizophrenia
This is a clinical trial in which 40 participants with schizophrenia will be randomized to 15 days of treatment with cariprazine (CAR) or brexpiprazole (BREX) in a single-blind manner.
- Conditions
- Schizoaffective Disorder, Schizophreniform Disorder, Schizophrenia
- Trial name
- NCT07715253
- Testing
- Brexpiprazole, Cariprazine, [11C] PHNO
- Volunteers
- 100 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia
Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis
This 52 week long study evaluates the effectiveness of aripiprazole versus risperidone in treating people with first-episode schizophrenia.
- Trial name
- NCT00320671
- Testing
- Aripiprazole, Risperidone
- Where
- United States
- Volunteers
- 198 people
- Sponsor
- Northwell Health
Schizophrenia, Schizoaffective Disorder
Efficacy of an Early Antipsychotic Switch in Case of Poor Initial Response to the Treatment of Schizophrenia
The main aim of the trial is to study whether a change of medication in non-responders to a two-weeks antipsychotic drug trial is more effective than continued treatment with the same antipsychotic.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT01029769
- Testing
- Olanzapine or amisulpride
- Where
- Germany
- Volunteers
- 350 people
- Sponsor
- Technical University of Munich
Schizophrenia, Schizoaffective Disorder
Clinical Estradiol Trial in Women With Schizophrenia
To investigate the 'estrogen-protection' hypothesis by comparing changes in psychotic symptoms between one group of patients receiving standard antipsychotic drug treatment plus placebo and a second matched group receiving…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00206570
- Testing
- Estradiol
- Where
- Australia
- Volunteers
- 100 people
- Sponsor
- Bayside Health
Schizophrenia, Schizophreniform Disorder
Pregnenolone Augmentation in the Treatment of Patients With Recent-Onset Schizophrenia
Pregnenolone (PREG) is a neurosteroid, which displays multiple effects on the central nervous system, and may be beneficial in the treatment of patients with schizophrenia.
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorders
- Trial name
- PREG-2008 (NCT00847600)
- Testing
- Pregnenolone
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Sha'ar Menashe Mental Health Center
Bipolar I Disorder, Bipolar II Disorder
Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder
This open-label study will utilize treatment with BXCL501 in order to assess the suitability of patient-and lay informant-assessed outcome measures for evaluation of severity of psychomotor agitation episodes in patients with…
- Conditions
- Bipolar I Disorder, Bipolar II Disorder, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT07116694
- Testing
- BXCL501 Sublingual Film
- Where
- 5 sites in United States
- Volunteers
- 33 people
- Sponsor
- BioXcel Therapeutics Inc
Psychosis, Schizophrenia Disorder
Cognitive Strategies in Early Psychosis 2
The goal of this clinical trial is to learn more about decision making in psychosis spectrum disorders, like schizophrenia. Participants will be people who have had symptoms of a psychosis spectrum disorder start within the last…
- Conditions
- Psychosis, Schizophrenia Disorder, Schizoaffective Disorder, Major Depressive Disorder With Psychotic Features
- Trial name
- COSTEP 2 (NCT07263022)
- Testing
- Modafinil, D-serine solution
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Minnesota
Schizophrenia
Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia
This study will determine the effectiveness of oral risperidone versus long-acting injectable risperidone in treating people with first-episode schizophrenia.
- Trial name
- NCT00330551
- Testing
- Oral Risperidone, Risperidone in Long-Acting Injectable Form (Consta)
- Where
- United States
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Schizophrenia, Schizoaffective Disorder
Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects
The purpose of this study is to determine if zonisamide SR will prevent weight gain in schizophrenic subjects who take olanzapine (Zyprexa)
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00734435
- Testing
- zonisamide SR plus olanzapine
- Where
- 9 sites in United States
- Volunteers
- 26 people
- Sponsor
- Orexigen Therapeutics, Inc
Schizophrenia, Schizoaffective Disorder
Minocycline Augmentation of Clozapine for Treatment Resistant Schizophrenia
This a randomized double-blind placebo controlled trial which aims to determine the beneficial effects of minocycline augmentation to clozapine in partial responders to Treatment Resistant Schizophrenia (TRS).
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT02533232
- Testing
- Minocycline
- Where
- 4 sites in Pakistan
- Volunteers
- 60 people
- Sponsor
- Pakistan Institute of Living and Learning
Delusional Disorder, Brief Psychotic Disorder
FEEL-GOOD: A Multicenter Trial of a Mindfulness-Based Group Therapy in Young Adults With Early Psychosis
FEEL-GOOD is a prospective multi-site single-blinded randomized controlled trial in young inpatients with acute early psychosis. Participants are randomized 1:1 to FEEL-GOOD plus treatment as usual (TAU) or TAU alone.
- Conditions
- Delusional Disorder, Brief Psychotic Disorder, Schizophreniform Disorder, Schizophrenia / Schizoaffective Disorder
- Trial name
- FEEL-GOOD (NCT07645443)
- Testing
- FEEL GOOD, Treatment as Usual (TAU)
- Where
- 8 sites in Germany
- Volunteers
- 252 people
- Sponsor
- Stephanie Mehl
Schizophrenia, Schizophreniform Disorder
DECIFER: Depression and Citalopram In First Episode Recovery
This study seeks to examine the effectiveness of citalopram added to treatment with any oral or injectable second-generation antipsychotic plus standardized psychoeducation in first episode schizophrenia patients.
- Trial name
- DECIFER (NCT01041274)
- Testing
- Citalopram, Psychoeducation, Cognitive Behavioral Therapy (CBT)
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- NYU Langone Health
Schizophrenia, Schizophreniform Disorder
Integrated Metacognitive Therapy in First Episode Psychosis
Insight, or lack of illness awareness, is a prominent and pressing clinical concern in the treatment and recovery of patients with psychotic disorders.
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
- Trial name
- IMT (NCT02131116)
- Testing
- Integrated Metacognitive Therapy, Treatment as Usual
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Indiana University
Schizophrenia, Schizo Affective Disorder
Young Adults With Violent Behavior During Early Psychosis (Aim 2)
This study aims to provide an evidence-based behavioral intervention to reduce violent behavior for individuals experiencing early psychosis.
- Conditions
- Schizophrenia, Schizo Affective Disorder, Schizophreniform Disorders, Delusional Disorder
- Trial name
- NCT05756855
- Testing
- adapted behavioral intervention
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Columbia University
Psychosis, Schizophrenia
Contrasting Group Therapy Methods for Psychosis
Current Canadian Clinical Practice guidelines emphasize the need for effective psychosocial adjuncts to pharmacotherapy for schizophrenia (Canadian Psychiatric Association 2005).
- Conditions
- Psychosis, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- MCT (NCT01764568)
- Testing
- Metacognitive Training (MCT), Cognitive Remediation (CR)
- Where
- Canada
- Volunteers
- 129 people
- Sponsor
- University of British Columbia
Schizophrenia and Related Disorders, Early Treatment-Resistance
The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
Schizophrenia (SZ) affects approximately 4.5 million people across the European Union (EU) and is associated with annual healthcare and societal costs of 29 billion Euros.
- Trial name
- INTENSIFY SZ (NCT05958875)
- Testing
- Clozapine, Second-line Antipsychotics (treatment as usual)
- Where
- 13 sites in Austria, Germany and 3 more
- Volunteers
- 418 people
- Sponsor
- Dr. Inge Winter
Schizophrenia, Schizoaffective Disorder
Study on the Safety of Risperidone on Obese or Overweight Patients With Schizophrenia
The purpose of this study is to evaluate the safety of risperidone treatment in patients who are overweight and/or obese.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00511628
- Testing
- Risperidone
- Volunteers
- 1,717 people
- Sponsor
- Janssen-Cilag, S.A.
Schizophrenia, Oxytocin
Adult Study Oxytocin - Behavioral
In this study, investigators will examine the behavioral effects and neurophysiological mechanisms of the pro-social neuropeptide oxytocin in patients with recent-onset schizophrenia and other psychotic disorders.
- Conditions
- Schizophrenia, Oxytocin, Social Cognition, Psychotic Disorders
- Trial name
- ASO-Behavioral (NCT02567032)
- Testing
- Oxytocin, Saline Nasal Spray
- Where
- 2 sites in United States
- Volunteers
- 324 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco